A Florida doctor, Simon Grinshteyn, pleaded guilty on March 23 in federal court in Boston to making false statements related to a multi-million-dollar health care fraud scheme involving unnecessary genetic testing and durable medical equipment.
The case highlights ongoing concerns about fraudulent billing practices that impact Medicare and the broader health care system. Authorities said the fraudulent activities resulted in Medicare paying more than $3.1 million for services based on false documentation.
According to court documents, between February 2020 and June 2020, Grinshteyn worked with a telemedicine company to sign off on pre-populated medical records and doctors’ orders for genetic testing and durable medical equipment that were not medically necessary. The documents made it appear as if Grinshteyn had provided legitimate consultations and examinations of Medicare beneficiaries or would provide further care. In reality, he generally did not contact the patients himself nor establish any provider-patient relationship with them. The signed orders were then used by suppliers and laboratories to submit claims to Medicare.
Grinshteyn was charged in January 2026 with one count of making false statements relating to health care matters. U.S. District Court Judge Angel Kelley scheduled sentencing for June 24, 2026. The charge carries a maximum sentence of five years in prison, three years of supervised release, and a fine up to $250,000 or twice the gross pecuniary gain or loss—whichever is greater. Sentencing will be determined according to federal guidelines.
United States Attorney Leah B. Foley announced the plea along with officials from several investigative agencies including Health and Human Services-Office of Inspector General; Federal Bureau of Investigations Boston Division; U.S. Postal Inspection Service’s Boston Division; Department of Labor Office of Inspector General; and Defense Criminal Investigative Service Northeast Field Office.
The outcome underscores efforts by law enforcement agencies to address fraud within federal health programs through coordinated investigations.
